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AbstrAct
The identification of the molecular mechanisms involved in the establishment 
of the resistant phenotype represents a critical need for the development of new 
strategies to prevent or overcome cancer resistance to anti-neoplastic treatments.
Breast cancer is the leading cause of cancer-related deaths in women, and 
resistance to chemotherapy negatively affects patient outcomes. Here, we investigated 
the potential role of miR-302b in the modulation of breast cancer cell resistance to 
cisplatin. 
miR-302b overexpression enhances sensitivity to cisplatin in breast cancer cell 
lines, reducing cell viability and proliferation in response to the treatment. We also 
identified E2F1, a master regulator of the G1/S transition, as a direct target gene 
of miR-302b. E2F1 transcriptionally activates ATM, the main cellular sensor of DNA 
damage. Through the negative regulation of E2F1, miR-302b indirectly affects ATM 
expression, abrogating cell-cycle progression upon cisplatin treatment. Moreover 
miR-302b, impairs the ability of breast cancer cells to repair damaged DNA, enhancing 
apoptosis activation following cisplatin treatment.
These findings indicate that miR-302b plays a relevant role in breast cancer cell 
response to cisplatin through the modulation of the E2F1/ATM axis, representing a 
valid candidate as therapeutic tool to overcome chemotherapy resistance. 
INtrODUctION
Breast cancer is the leading cause of cancer-related 
deaths in women [1]. Clinically, this heterogeneous 
disease is categorized into four major molecular subtypes: 
Luminal A, Luminal B, HER2 type and triple-negative/
basal-like. Triple-negative breast cancer (TNBC) 
constitutes approximately 15 to 20% of all breast cancer 
cases, with the worst outcome of all subtypes [2]. For 
patients affected by TNBC, targeted therapies are not 
available and chemotherapy has a limited duration of 
effect in later stages of the disease [3].
Patients usually display a good initial response to 
cisplatin-based chemotherapy. However, drug resistance 
is a fundamental problem in breast cancer management, 
and is responsible for most cases of treatment failure 
in patients with metastatic cancer [4, 5]. Cisplatin 
cytotoxicity to normal tissues and cancer cell acquired 
resistance reduce the clinical efficacy of this drug [6]. 
However, the molecular mechanisms determining breast 
cancer resistance to this drug still remain not completely 
understood. 
MicroRNAs (miRNAs) are short (19-22 nucleotide) 
non-coding RNAs known to alter gene expression at the 
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post-transcriptional level [7, 8]. MicroRNA expression 
profiling was shown to be associated with tumor 
development, progression and response to therapy, 
suggesting their possible use as diagnostic, prognostic 
and predictive biomarkers [9]. Presumably, miRNAs 
evolved to allow organisms and cells to effectively deal 
with cellular stress[10]. Recent studies demonstrated 
that a single miRNA can impact hundreds of targets [11], 
and that multiple miRNAs can affect a single target [12], 
pointing out to the broad implications of miRNAs in 
the modulation of important cellular processes. Indeed, 
several experimental and clinical findings have also 
implicated miRNAs in the response to chemotherapy 
[13], demonstrating a role for miRNAs in the modulation 
of genes involved in DNA repair [14, 15].
The miR-302 cluster, which consists of miR-302a, 
-302a*, -302b, -302b* -302c, -302c*, -302d, -367 and 
-367*, was first found to be functionally correlated with 
self-renewal and proliferation properties in the stemness 
maintenance of embryonic stem cells (ESCs) [16, 17]. 
Furthermore, tumor-related miRNA studies proved 
the potential role of miR-302b as tumor-suppressor in 
different cancer models [18-25]. miR-302b is also reported 
to be down modulated, compared to normal tissues, in 
breast cancer [26]. Recently, by microarray analysis, 
miR-302b was identified as closely associated with 
the occurrence and development of breast cancer [27]. 
Moreover, Liang Z. et al. demonstrated that miR-302a 
sensitized radioresistant breast cancer cells to radiation 
therapy in vitro and in vivo and reduced the expression of 
AKT1 and RAD52 [28].
In a previous work, we demonstrated that miR-302b 
represents a biomarker in human ovarian carcinoma cells 
able to predict response to cisplatin treatment [29]. In this 
study we aimed to demonstrate that miR-302b sensitizes 
breast cell lines to cisplatin treatment by regulating E2F1 
expression and cellular DNA Damage Response (DDR) 
mechanisms. 
rEsULts
mir-302b sensitizes breast cancer cell lines to 
cisplatin treatment
Our previous findings demonstrated that high levels 
of miR-302b represent a predictive biomarker for the 
response to cisplatin treatment of ovarian cancer cells. 
Moreover, reduced levels of miR-302b in breast cancer 
tumors suggest a potential role for this microRNA as a 
tumor suppressor. Based on these observations, we first 
Figure 1: mir-302b enhances cisplatin sensitivity in breast cancer cell lines. A. MDA-MB-231 cell viability was analyzed 
after miR-302b precursor or scrambled transfection and after 4 and 24 hours of cisplatin treatment. Cells were stained with Trypan blue 
and counted. Data are representative of three independent experiments performed at least in triplicate. b. MTS assay on MDA-MB-231 
cells transfected with miR-302b precursor or scrambled and treated 4 or 24 hours with cisplatin. Absorbance at 490nm (according to 
manufacturers’ instructions) is reported. Data are the average of two independent experiments performed at least in triplicate. c. Colony 
formation assay from MDA-MB-231 cells transfected with a miR-302b expression vector compared to the empty vector control. D. 
Quantitative analysis of the experiment shown in (C). P-values were calculated using two-tailed Student’s t-test. *=p < 0.05; **=p < 0.01; 
***=p < 0.001
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aimed to assess the ability of miR-302b to mediate breast 
cancer sensitivity to cisplatin.
To this aim, MDA-MB-231 TNBC cells were 
transiently transfected with miR-302b precursor or 
scrambled control (miR-302b and scr). Forty-eight hours 
following transfection, cells were treated with cisplatin 
(100µM) or left untreated for 4 or 24 hours. Transfection 
efficiency was evaluated by RealTime PCR as shown in 
Supplementary Figure 1A. As shown in Figure 1A, miR-
302b transfection enhanced breast cancer cell sensitivity to 
cisplatin. Similar results were also obtained using different 
TNBC (BT549) and luminal breast cancer (T47D) cell 
lines (Supplementary Figure 1B and 1C), indicating that 
miR-302b modulates cisplatin resistance in different in 
vitro models of breast cancer. MTS assay performed on 
MDA-MB-231 cells confirmed the inhibitory effects of 
miR-302b on cell growth following cisplatin treatment 
(Figure 1B). 
To further confirm that miR-302b overexpression 
enhances cisplatin sensitivity of breast cancer cells, colony 
assay was also performed. MDA-MB-231 cells were 
transfected with miR-302b expression vector or with the 
corresponding empty vector, and treated with cisplatin for 
4 and 24 hours. As shown in Figure 1C-1D, a significant 
reduction in the number of colonies was observed when 
MDA-MB-231 cells were transfected with miR-302b, 
compared to empty-transfected cells, following cisplatin 
treatment. 
These results demonstrate that miR-302b sensitizes 
breast cancer cells to cisplatin treatment.
mir-302b directly targets E2F1
To identify the mechanisms by which miR-302b 
sensitizes breast cancer cells to cisplatin treatment, we 
performed an in silico analysis of the potential target genes 
of this microRNA. TargetScan algorithm (www.targetscan.
Figure 2: mir-302b directly targets E2F1. A. Schematic representation of miR-302b targeting site on wild type and mutant E2F1-
3’UTR. b.-c. Real Time PCR b. and Western Blot c. evaluation of E2F1 expression levels on MDA-MB-231 cells transfected with 
miR-302b precursor or a scrambled oligonucleotide after 48h. D. Luciferase activity of E2F1-3′UTR and E2F1-3′UTR mutated plasmids 
transfected in MDA-MB-231 cells in the presence of miR-302b precursor or scrambled negative control. Data are the average of two 
independent experiments +S.D. calculated on 3 different replicates. P-values were calculated using two-tailed Student’s t-test. *=p < 0.05; 
**=p < 0.01; ***=p < 0.001
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org) identified E2 transcriptor factor 1 (E2F1) as predicted 
target gene for miR-302b (Figure 2A). The E2F family of 
transcription factors plays a crucial role in the control of 
cell proliferation, regulating the expression of many genes 
required for entry and progression through the S phase of 
the cell cycle [30]. Moreover, E2F1 protein is stabilized 
and its levels are increased in response to DNA damage 
[31-33]. 
As shown in Figure 2B-2C, miR-302b 
overexpression in MDA-MB-231 cells resulted in the 
decrease of E2F1 expression both at the mRNA (Figure 
2B) and protein (Figure 2C) levels.
To demonstrate the direct targeting of E2F1 3’-UTR 
by miR-302b, a luciferase reporter assay was performed. 
To this aim, the 3’-UTR region of E2F1 including 
the predicted binding site for miR-302b was cloned 
downstream the luciferase reporter gene. MDA-MB-231 
cells were co-transfected with miR-302b precursor or 
scrambled negative control and the reporter vector. As 
shown in Figure 2D, a significant decrease in luciferase 
activity was observed in miR-302b transfected cells as 
compared to scrambled transfected cells. Of note, deletion 
of the miR-302b binding site on the E2F1 3’-UTR reporter 
vector (Figure 2A) partially rescued the inhibitory effect 
of miR-302b on luciferase expression (Figure 2D).
Taken together, these findings indicate that E2F1 is 
a new target of miR-302b.
mir-302b regulates AtM through E2F1
ATM (Ataxia-Telangiectasia Mutated) is one of the 
most important serine/theronine kinase that transduces 
DNA damage signals to downstream mediators involved 
in the cellular DDR [34, 35]. ATM is primarily activated 
in response to DNA Double Strand Breaks (DSBs) 
due to cisplatin treatment, mediating cell cycle arrest, 
repair of damaged DNA and cellular apoptosis [14]. It 
was previously demonstrated that E2F1 activates ATM 
promoter activity, resulting in increased ATM mRNA 
and protein levels [36]. Since miR-302b negatively 
regulates E2F1, we hypothesized that up-regulation of 
Figure 3: mir-302b indirectly targets AtM. A.-b. MDA-MB-231 cells were transfected with miR-302b precursor or scrambled 
control and RNA and proteins were collected after 48h. ATM mRNA levels were analyzed by RT-qPCR A. and protein expression was 
evaluated by Western Blot b. c. Relative Luciferase activity in MDA-MB-231 cells for ATM human promoter co-transfected with miR-
302b precursor or scrambled for 48h. D. ATM expression after miR-302b precursor or scrambled transfection in the presence of E2F1 
expression vector or its empty control in MDA-MB-231. *=p < 0.05; **=p < 0.01; ***=p < 0.001
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this microRNA could result in reduced transcriptional 
activation of ATM promoter. Accordingly, we observed 
a significant decrease of both ATM mRNA and protein 
levels when miR-302b was expressed in MDA-MB-231 
cells (Figure 3A and 3B). However, in silico analysis 
of ATM 3’UTR did not identify potential binding sites 
for miR-302b (data not shown). Then, we hypothesized 
that miR-302b could indirectly affect ATM expression 
through E2F1. To validate this hypothesis, we performed a 
luciferase assay by transfecting MDA-MB-231 cells with 
a reporter plasmid containing the luciferase gene under 
the transcriptional control of human ATM gene [36] in the 
presence of miR-302b precursor or a scrambled negative 
control. Figure 3C shows that the transcriptional activity 
of ATM promoter was significantly reduced by miR-
302b transfection compared to scrambled transfected 
cells (Figure 3C). To confirm that miR-302b-mediated 
regulation of ATM gene expression was dependent on 
E2F1 transcriptional activity, MDA-MB-231 cells were 
transfected with miR-302b precursor or a scrambled 
negative control following transfection of E2F1 
expression vector (not including its 3’-UTR) or its empty 
negative control (Supplementary Figure 2A-2B). Real 
Time analysis confirmed the down regulation of ATM 
expression following miR-302b transfection. Conversely, 
exogenous expression of E2F1 rescued the expression of 
Figure 4: mir-302b affects cell cycle progression after cisplatin treatment in MDA-Mb-231. A. Cell cycle analysis of 
MDA-MB-231 transfected with miR-302b precursor or scrambled and treated with cisplatin. Cells were fixed and stained with propidium 
iodide and analyzed by flow cytometry. Data obtained were analyzed using ModFit software. Cells in G1 and in G2 phase of cell cycle are 
reported in red, cells in S phase are indicated with white and blue bars. Flow cytometry plots shown are representative of three independent 
experiments. b. Graphic representation of cell distribution in G1, S, or G2 phase (blue, red and green, respectively) of the experiment 
shown in A.. Percentages of cells in each phase of the cell cycle are the average of three independent experiments. 
Figure 5: mir-302b affects DNA repair mechanisms. A. Homologous recombination (HR) and b. Non-Homologus End Joining 
(NHEJ) assays using HeLa-DR-13-9 and HeLa-EJ-5 cells (respectively) transfected with miR-302b precursor or scrambled control (scr). 
After generating a double-strand DNA break by expressing the I-SceI endonuclease, functional HR and NHEJ results in the conversion of 
cells to positive for GFP. The percentage of GFP-positive cells was determined by flow cytometry. Reported data are representative of two 
experiments performed in triplicate and mean + SD is reported. Statistical significance was analyzed by the unpaired Student’s t-test. *=p 
< 0.05; **=p < 0.01; ***=p < 0.001
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ATM also in the presence of miR-302b.
Finally, we demonstrated that miR-302b negatively 
regulates E2F1 and, indirectly, ATM, using two different 
cellular models of breast cancer, BT-549 (TNBC) and 
T47D (luminal breast cancer). As shown in Supplementary 
Figure 2C-2E, exogenous expression of miR-302b resulted 
in downregulation of E2F1 and ATM also in these systems.
Taken together, these data indicate that miR-302b, 
by targeting E2F1, negatively affects ATM expression 
levels in breast cancer cells of different origin.
mir-302b affects cell cycle progression after 
cisplatin treatment
Since E2F1 regulates cell proliferation by 
modulating S-phase entry and progression, we decided 
to investigate the potential role of miR-302b in cell cycle 
control in response to cisplatin treatment. MDA-MB-231 
(Figure 4) and BT549 (Supplementary Figure 3) breast 
cancer cells were transiently transfected with miR-302b 
precursor or scrambled negative control, treated for 4h 
with cisplatin, collected at 24h from the treatment and 
analyzed by flow-cytometry following propidium-iodide 
staining. No significant alteration of cell cycle distribution 
was observed between untreated miR-302b-transfected or 
scrambled-transfected MDA-MB-231 cells. Conversely, 
following cisplatin treatment, miR-302b-transfected cells 
displayed a higher accumulation in the S phase of the cell 
cycle higher compared to negative control-transfected 
cells (61% vs 50%). Similar results were obtained using 
BT549 cells following miR-302b transfection and cisplatin 
treatment (Supplementary Figure 3). These results indicate 
that overexpression of miR-302b inhibits cell-cycle 
transition through S-phase following cisplatin treatment 
of breast cancer cells. 
Figure 6: mir-302b effects on apoptosis. A. Caspase 3/7 activation assay following transient transfection of MDA-MB-231 cells 
with miR-302b precuror or scrambled control and upon cisplatin treatment for 4 and 24 hours. Data are the average of three independent 
experiments. P-values were calculated using two-tailed Student’s t-test. *=p < 0.05; **=p < 0.01; ***=p < 0.001. b.-c. Caspase-3 b. and 
PARP c. protein expression evaluated by Western Blot after miR-302b or scrambled transfection and cisplatin treatment for 4 and 24 hours 
in MDA-MB-231 cells.
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mir-302b overexpression impairs Homologus 
recombination and Non-Homologus End Joining 
DNA repair mechanisms
Our data so far demonstrated that miR-302b 
overexpression in breast cancer cell lines leads to 
sensitization to cisplatin treatment, by targeting E2F1 
and ATM. Since ATM plays a key role in the molecular 
mechanisms of DNA repair, we also investigated whether 
miR-302b overexpression could result in the impairment 
of these mechanisms, cycle checkpoint activation and, 
eventually, apoptosis or senescence [37]. Following 
DNA DSBs, the two major pathways involved in DNA 
repair are Homologous Recombination (HR) and Non-
Homologous End Joining (NHEJ) [38]. We evaluated 
the effects of miR-302b overexpression on both DDR 
mechanisms using two established assays based on HeLa 
derived cells (HeLa-DR 13-9 and HeLa-EJ-5 for HR 
and NHEJ, respectively) with the specific recombination 
substrate DNA integrated in the genome to study each 
DSB repair pathway [39, 40]. In both systems, if HR-
mediated or NHEJ DNA-repair occurs, the recombination 
generates an active GFP allele that can be revealed by 
detection and quantification of green-fluorescent cells. We 
transfected HeLa-DR13-9 and HeLa-EJ5 cells with either 
a miR-302b precursor or scrambled control and, two days 
later, with plasmid encoding for the I-SceI endonuclease 
to induce DNA damage. The percentage of GFP-positive 
cells (reflecting the efficiency of HR-mediated and NHEJ 
DNA-repair) was then assessed by flow cytometry at 72 
h after the second transfection. As shown in Figure 5A 
and 5B, miR-302b expression resulted in about 30% 
and 15% reduction of GFP-positive cells. RNA was 
extracted from HeLa-DR13-9 cells to verify miR-302b 
transfection and down-regulation of E2F1 and ATM 
mRNA levels (Supplementary Figure 4). All together 
these results indicate that miR-302b improve sensitivity 
to chemotherapy in breast cancer cell lines negatively 
affecting DNA-repair. 
mir-302b overexpression and cisplatin treatment 
induce apoptosis
We have demonstrated that miR-302b sensitizes 
breast cancer cell lines to cisplatin treatment by targeting 
directly E2F1 and indirectly ATM, reducing cell growth. To 
evaluate whether miR-302b expression could also activate 
apoptosis in response to cisplatin treatment, we performed 
Caspase 3/7 activation following transient transfection of 
miR-302b in MDA-MB-231 cells. As shown in Figure 
6A, significant Caspase activation induction was observed 
at 4 and 24 hours upon cisplatin treatment (Figure 6A). 
Similarly, miR-302b overexpression resulted in enhanced 
Caspase 3/7 activation also in BT549 cells (Supplementary 
Figure 5).
Accordingly, as shown in Figure 6B and 6C, western 
blot analysis of MDA-MB-231 transiently transfected 
with miR-302b and treated with cisplatin 24h showed a 
significant PARP degradation and Caspase-3 activation 
compared to scrambled negative control transfected cells.
These results demonstrated that miR-302b 
overexpression enhances cisplatin sensibility of breast 
cancer cells, by inducing apoptosis.
DIscUssION
Breast cancer patients usually have a good initial 
response to cisplatin-based chemotherapy but the 
insurgence of drug resistance represents one of the major 
causes of treatment failure, especially for patients with 
metastatic disease [4, 5].
A growing body of evidence demonstrated a 
correlation between miRNAs expression and tumor 
chemo- and radiosensitivity [28, 41, 42], further 
supporting the strong clinical relevance of microRNAs.
In a previous study, we demonstrated that miR-302b 
acts as chemo-sensitizer in human ovarian carcinoma cell 
lines by targeting HDAC4, and may represent a biomarker 
able to predict response to cisplatin [29]. 
The aim of this study was to evaluate the role 
of miR-302b in the modulation of breast cancer cell 
sensitivity to cisplatin, also investigating the molecular 
mechanisms affected by this microRNA and involved in 
cancer cell resistance to these treatments.
Here, we first analyzed cisplatin sensitivity of 
three different breast cancer cell lines, MDA-MB-231 
and BT549 (triple negative) and T47D (luminal), upon 
miR-302b overexpression. Our results indicate that miR-
302b overexpression induces a significant decrease of cell 
viability and proliferation following cisplatin treatment 
in different breast cancer cell lines, suggesting that miR-
302b could play an important role in mediating cisplatin 
sensitivity of both TNBC and luminal breast cancer cells.
In silico analysis allowed us to the identify E2F1, a 
master regulator of the G1/S transition, as a new potential 
miR-302b target. Our experimental data demonstrated that 
miR-302b negatively modulates E2F1 expression at both 
mRNA and protein levels. Luciferase assays confirmed the 
direct targeting of E2F1 3’-UTR by miR-302b. However, 
mutation of E2F1 3’-UTR sequence in the potential miR-
302b target site only partially abrogated miR-302b control 
of E2F1 expression, suggesting that other non-canonical 
binding sites for this microRNA could be present. 
Accordingly with the role of E2F1 in the control of 
cell-cycle progression, we confirmed that down-regulation 
of this protein upon miR-302b overexpression results in 
a slower transition through the S-phase of the cell cycle, 
following cisplatin treatment. Of note, major alterations of 
the cell cycle progression were not observed in untreated 
cells, suggesting that other factors, such as the other 
members of the E2F family, might compensate for the 
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absence of E2F1 following miR-302b overexpression. 
However, following cisplatin treatment, the stronger 
accumulation in the G1/S phase of the cell cycle mediated 
by miR-302b suggests the presence of specific molecular 
pathways relying on E2F1. 
It has been widely demonstrated that E2F1 elevates 
ATM promoter activity and enhances ATM mRNA and 
protein levels [36]. This protein activates a signaling 
cascade that leads to the immediate triggering of DNA-
repair mechanisms, [34, 43] and it is primarily activated in 
response to DSBs due to cisplatin treatment [14]. Usually, 
cells activate multiple DNA repair mechanisms to remove 
cisplatin-damaged DNA. These DNA repair systems are 
detrimental to the cytotoxic efficacy of the drug. Indeed, 
increased DNA repair capacity of cancer cells is a key 
mechanism involved in cisplatin resistance [44]. Since our 
data demonstrated that miR-302b directly targets E2F1, we 
also analyzed ATM expression. Interestingly we found that 
miR-302b negatively regulates ATM expression indirectly, 
at least in part through the direct down-regulation of E2F1 
expression. In the presence of higher levels of miR-302b, 
reduced levels of E2F1 result in the partial abrogation of 
ATM activation, affecting cancer cell ability to repair DNA 
and proliferate. Accordingly, here we show that exogenous 
expression of miR-302b negatively affects the ability of 
breast cancer cells to repair damaged DNA by NHEJ and 
HR, which suggests that miR-302b correspond to cellular 
alteration following DNA-damaging agents treatment.
Consequently, down-regulation of ATM-dependent 
mechanisms of DDR leads to enhanced cell death 
following cisplatin treatment. In fact, our results show 
apoptosis activation following miR-302b overexpression 
and cisplatin treatment, as indicated by Caspase-3 and 
PARP cleavage.
The advantage of miRNAs is their ability to 
affect multiple targets with a single hit, thus resulting a 
whole network of interacting molecules. However, we 
found that miR-302b, through the negative regulation 
of E2F1, targets ATM and we could confirm that miR-
302b replacement therapy might enhance sensitivity 
to chemotherapy in breast cancer cells, targeting genes 
involved in mechanisms such as cell cycle and DDR 
frequently altered in cancer. 
In conclusion our study demonstrates that miR-
302b overexpression increases sensitivity of breast cancer 
cell lines to cisplatin by targeting E2F1 and ATM, further 
compromising the control of cell-cycle progression and 
DDR mechanisms.
These findings indicate that miR-302b might 
represent a biomarker to predict response to cisplatin 
treatment in breast cancer patients, supporting this 
microRNA as potential therapeutic tool to overcome 
chemotherapy resistance.
MAtErIALs AND MEtHODs
cell lines, transfections and treatments
All the cell lines used were purchased from the 
American Type Culture Collection (ATCC). MDA-
MB-231, BT549 and T47D cells were grown in Roswell 
Park Memorial Institute 1640 (RPMI) medium, containing 
10% heat-inactivated fetal bovine serum (FBS), 2 mM 
l-glutamine and 100 U/mL penicillin-streptomycin. MDA-
MB-231, BT-549 and T47D were treated for 4 and 24 
hours with cisplatin 100 µM (Sigma).
For transfection experiments, cells were seeded in 
6-well plates at 2x105/well or in 96-well at 2x103/well and 
transfected with 100nM of hsa-miR-302b-3p Pre-miRTM 
miRNA Precursor (Ambion) or Pre-miRTM Negative 
Control #1 (Ambion) or different amounts (5-200ng) of 
indicated plasmid DNAs. All transfections were carried 
out with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions.
Quantitative real-time Pcr for mirNA and 
mRNA quantification
Total RNA was extracted using TRIzol (Invitrogen) 
according to manufacturer’s instructions. Quantitative real-
time PCR (qRT-PCR) were performed using the TaqMan 
Fast-PCR kit (Applied Biosystems) according to the 
manufacturer’s instructions, using the appropriate TaqMan 
probes for miRNA and gene quantification, followed by 
detection with the 7900HT Sequence Detection System 
(Applied Biosystems). All reactions were performed in 
triplicate. Simultaneous quantification of RNU44 was 
used as reference for miRNA quantification. Simultaneous 
quantification of GAPDH mRNAs was used as reference 
for gene quantification. The comparative cycle threshold 
(Ct) method for relative quantification of gene and miRNA 
expression (User Bulletin #2; Applied Biosystems) was 
used to determine miRNA and gene expression levels. 
cell viability
MDA-MB-231, BT549 and T47D cells seeded in 
6 wells at a density of 2x105 cells/well were transfected 
with 100nM hsa-miR-302b-3p Pre-miRTM miRNA 
Precursor (Ambion) or Pre-miRTM Negative Control #1 
(Ambion). After 48h of culture, cells were treated or not 
with cisplatin for 4 and 24 hours. Cells were counted 
using Trypan Blue Stain 0.4% (GIBCO) at 24h following 
the treatment. Data are representative of at least two 
independent experiments performed in triplicate and mean 
+ SD is reported. Statistical significance was analyzed by 
the unpaired Student t-test.
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Mts assay
MDA-MB-231 cells seeded in 96 wells at a density 
of 2x103 cells/well were transfected with 100nM hsa-
miR-302b-3p Pre-miRTM miRNA Precursor (Ambion) or 
Pre-miRTM Negative Control #1 (Ambion). After 48h of 
culture, cells were treated or not with cisplatin for 4 and 
24 hours. Cells were then incubated with MTS solution 
(Promega) according to manufacturer’s instructions. 
Cell growth was assessed based on optical density (OD) 
at 490nm using a spectramax 340 microtiter microplate 
reader (Molecular Devices). The mean ± S.D. of two 
independent experiments performed in triplicate is 
reported. Statistical significance was analyzed by the 
unpaired Student t-test.
colony forming assay
MDA-MB-231 cells were plated in 100-mm dishes 
and transfected with 500ng of miR-302b expression 
plasmid or empty control (OriGene). After 48 h, Geneticin 
(Invitrogen) was added at the final concentration of 500 
μg/mL. Three weeks after the onset of drug selection, 
colonies were stained with crystal violet acquired using 
the QuantityOne software (Biorad) and counted. Data are 
representative of one experiment performed in triplicate 
and mean + SD is reported. Statistical significance was 
analyzed by the unpaired Student t-test.
Plasmid construction
The E2F1 3′ untranslated region (UTR) reporter 
construct, including the binding site for miR-302b and 
cloned into the pGL3 control vector (Promega, Madison, 
WI) downstream of the luciferase gene was previously 
described [45]. Mutations of the miR-302b binding site 
in the E2F1 3′-UTR were introduced using the Quick-
Change Lightning Site-Directed Mutagenesis kit (Agilent 
Technologies, Santa Clara, CA), according to the 
manufacturer’s instructions. 






E2F1 Mut Fw 
5’-gcgtgtaggacggtgagctgtcttaaaggtttttt-3’ E2F1 Mut Rev 
5’-aaaaaacctttaagacagctcaccgtcctacacgc-3’
The luciferase reporter plasmid ATM-Luc containing 
the human ATM promoter was kindly provided by Dr. 
Ginsberg (Department of molecular Cell Biology, The 
Weizmann Institute of Science, Rehovot 76100, Israel). 
The E2F1 expression vector was purchased from Addgene 
(Plasmid #21667) [46].
Luciferase assays for target and promoter 
identification
Luciferase reporter vectors (see above) and 10 ng 
of the pRL-SV40 (Renilla) control vector (Promega), 
and 100 nM miR-302b or scrambled sequence miRNA 
control (Ambion Inc, Austin, TX) were co-transfected into 
MDA-MB-231 cells in 12-well plates. Firefly luciferase 
activity was measured with the Dual Luciferase Assay 
Kit (Promega) 24h after transfection and normalized for 
the Renilla luciferase reference plasmid. Reporter assays 
were carried out in at least in quadruplicate and the mean 
(representative of at least two independent experiments) ± 
S.D. was reported. Statistical significance was analyzed by 
the unpaired Student t-test. 
Western blot analyses
Protein extraction and western blots were performed 
as previously described [47]. Protein concentration was 
detected with Bradford method. The antibodies used were: 
anti-E2F1 (sc-251, Santa Cruz Inc), anti-ATM (sc-23921, 
Santa Cruz Inc), anti-PARP (9532, Cell Signaling), anti-
Caspase-3 (9662, Cell Signaling) anti-β actin (sc-47778, 
Santa Cruz Inc), anti-vinculin (sc-73614, Santa Cruz Inc).
Apoptosis assay
Apoptosis was quantified using Caspase-Glo 
3/7 assay (Promega) according to the manufacturer’s 
instructions on a Bio-Tek Synergy HT multi detection 
microplate reader. The assay was performed three times 
in triplicate and the mean + S.D. was reported. Statistical 
significance was analyzed by the unpaired Student t-test.
FAcs analysis
Cells were trypsinized, washed in PBS and fixed 
in 70% ethanol for 2h at -20°. After fixation, cells were 
washed in PBS and centrifuged for 5 min at 1200 rpm. 
Cells were resuspended in PBS containing 10mg/ml 
propidium iodide (Roche) and incubated for 20 min at 
37°C. Cells were analyzed using FACS-Calibur flow 
cytometer and the results were further analyzed with the 
ModFit software, v3.2 (Verity Software House). The assay 
was performed three times in triplicate and the mean + 
S.D. was reported. Statistical significance was analyzed 
by the unpaired Student t-test.
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DNA repair assays
HR (Homologous Recombination) and NHEJ 
(Non-Homologous End Joining) assays were performed 
as previously described [39, 40]. Briefly, HeLA-DR13-9 
or HeLa-EJ-5 cells were transfected with 30pmol of hsa-
miR-302b-3p Pre-miRTM miRNA Precursor (Ambion) 
or Pre-miRTM Negative Control #1 (Ambion). On day 2, 
cells were transferred to 35 mm dishes. On day 3, cells 
were transfected with 50 pmol of hsa-miR-302b-3p Pre-
miRTM miRNA Precursor (Ambion) or Pre-miRTM Negative 
Control #1 (Ambion) along with I-SceI expression vector 
to induce DNA DSB. On day 6, cells were harvested 
and GFP positive cells were counted using a FACS 
Calibur flow cytometer (Becton-Dickinson). For each 
experimental point, at least 10,000 cells were analyzed. 
Data are representative of two independent experiments 
performed in triplicate and mean + SD is reported.
Abbreviations
E2F1: E2 transcriptor factor 1
ATM: Ataxia-Telangiectasia Mutated
DDR: DNA Damage Response
HR: Homologus Recombination
NHEJ: Non-Homologus End Joining 
DSB: Double Strand Breaks
AckNOWLEDgMENts
A.C. is recipient of a “Fondazione Andrea e Libi 
Lorini” Fellowship for Cancer Research. Authors express 
their gratitude to Dr. Jeffrey D. Parvin and to the DDR 
group of the Ohio State University. Special thanks go to 
Dr. Ginsberg and to Dr. David M. Livingston that kindly 
provided ATM-luc and E2F1 plasmids.
This work was financially supported by 
Pelotonia (D.P.) as well as a Research Grant from NIH 
(U01CA152758) (C.M.C.).
Authors’ contribution
A.C. and D.P. conceived the project and wrote 
the manuscript. A.C., D.P. and D.C. performed the 
experiments and analyzed the data. C.M.C., D.P., M.V.I., 
A.B., E.T. and V.C. supervised the project. C.M.C., M.V.I. 
and E.T. edited the manuscript.
cONFLIcts OF INtErEsts
The authors declare no conflict of interests.
rEFErENcEs
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and 
Forman D. Global cancer statistics. CA: a cancer journal 
for clinicians. 2011; 61:69-90.
2. Boyle P. Triple-negative breast cancer: epidemiological 
considerations and recommendations. Annals of oncology. 
2012; 23 Suppl 6:vi7-12.
3. Crown J, O’Shaughnessy J and Gullo G. Emerging targeted 
therapies in triple-negative breast cancer. Annals of 
oncology. 2012; 23 Suppl 6:vi56-65.
4. Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, 
Nikcevich D, Mattar B and Perez EA. A Phase II trial of 
docetaxel and carboplatin administered every 2 weeks 
as preoperative therapy for stage II or III breast cancer: 
NCCTG study N0338. American journal of clinical 
oncology. 2013; 36:540-544.
5. Mayer IA, Abramson VG, Lehmann BD and Pietenpol 
JA. New strategies for triple-negative breast cancer—
deciphering the heterogeneity. Clinical cancer research. 
2014; 20:782-790.
6. Kelland LR. Preclinical perspectives on platinum resistance. 
Drugs. 2000; 59 Suppl 4:1-8; discussion 37-38.
7. Filipowicz W, Bhattacharyya SN and Sonenberg N. 
Mechanisms of post-transcriptional regulation by 
microRNAs: are the answers in sight? Nature reviews 
Genetics. 2008; 9:102-114.
8. Bartel DP. MicroRNAs: target recognition and regulatory 
functions. Cell. 2009; 136:215-233.
9. Iorio MV and Croce CM. MicroRNA dysregulation 
in cancer: diagnostics, monitoring and therapeutics. A 
comprehensive review. EMBO molecular medicine. 2012; 
4:143-159.
10. Hermeking H. MicroRNAs in the p53 network: 
micromanagement of tumour suppression. Nature reviews 
Cancer. 2012; 12:613-626.
11. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, 
Khanin R and Rajewsky N. Widespread changes in protein 
synthesis induced by microRNAs. Nature. 2008; 455:58-63.
12. Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, Zhan R 
and He X. Multiple microRNAs modulate p21Cip1/Waf1 
expression by directly targeting its 3’ untranslated region. 
Oncogene. 2010; 29:2302-2308.
13. Allen KE and Weiss GJ. Resistance may not be futile: 
microRNA biomarkers for chemoresistance and potential 
therapeutics. Molecular cancer therapeutics. 2010; 9:3126-
3136.
14. Hu H and Gatti RA. MicroRNAs: new players in the DNA 
damage response. Journal of molecular cell biology. 2011; 
3:151-158.
15. Landau DA and Slack FJ. MicroRNAs in mutagenesis, 
genomic instability, and DNA repair. Seminars in oncology. 
2011; 38:743-751.
Oncotarget796www.impactjournals.com/oncotarget
16. Ren J, Jin P, Wang E, Marincola FM and Stroncek 
DF. MicroRNA and gene expression patterns in the 
differentiation of human embryonic stem cells. Journal of 
translational medicine. 2009; 7:20.
17. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha 
KY, Chung HM, Yoon HS, Moon SY, Kim VN and Kim 
KS. Human embryonic stem cells express a unique set of 
microRNAs. Developmental biology. 2004; 270:488-498.
18. Wang L, Yao J, Zhang X, Guo B, Le X, Cubberly M, Li 
Z, Nan K, Song T and Huang C. miRNA-302b suppresses 
human hepatocellular carcinoma by targeting AKT2. 
Molecular cancer research. 2014; 12:190-202.
19. Wang L, Yao J, Shi X, Hu L, Li Z, Song T and Huang C. 
MicroRNA-302b suppresses cell proliferation by targeting 
EGFR in human hepatocellular carcinoma SMMC-7721 
cells. BMC cancer. 2013; 13:448.
20. Chen PH, Shih CM, Chang WC, Cheng CH, Lin CW, Ho 
KH, Su PC and Chen KC. MicroRNA-302b-inhibited E2F3 
transcription factor is related to all trans retinoic acid-
induced glioma cell apoptosis. Journal of neurochemistry. 
2014; 131:731-742.
21. Zhang M, Yang Q, Zhang L, Zhou S, Ye W, Yao Q, Li 
Z, Huang C, Wen Q and Wang J. miR-302b is a potential 
molecular marker of esophageal squamous cell carcinoma 
and functions as a tumor suppressor by targeting ErbB4. 
Journal of experimental & clinical cancer research. 2014; 
33:10.
22. Zhu R, Yang Y, Tian Y, Bai J, Zhang X, Li X, Peng Z, 
He Y, Chen L, Pan Q, Fang D, Chen W, Qian C, Bian X 
and Wang R. Ascl2 knockdown results in tumor growth 
arrest by miRNA-302b-related inhibition of colon cancer 
progenitor cells. PloS one. 2012; 7:e32170.
23. Khalili M, Sadeghizadeh M, Ghorbanian K, Malekzadeh R, 
Vasei M and Mowla SJ. Down-regulation of miR-302b, an 
ESC-specific microRNA, in Gastric Adenocarcinoma. Cell 
journal. 2012; 13:251-258.
24. Tabrizi M, Khalili M, Vasei M, Nouraei N, Mansour Samaei 
N, Khavanin A, Khajehei M and Mowla SJ. Evaluating 
the miR-302b and miR-145 expression in formalin-fixed 
paraffin-embedded samples of esophageal squamous cell 
carcinoma. Archives of Iranian medicine. 2015; 18:173-
178.
25. Ge T, Yin M, Yang M, Liu T and Lou G. MicroRNA-302b 
suppresses human epithelial ovarian cancer cell growth by 
targeting RUNX1. Cellular physiology and biochemistry : 
international journal of experimental cellular physiology, 
biochemistry, and pharmacology. 2014; 34:2209-2220.
26. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, 
Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward 
MR, Yao G, Medina A, O’Brien-Jenkins A, Katsaros D, 
Hatzigeorgiou A, Gimotty PA, et al. microRNAs exhibit 
high frequency genomic alterations in human cancer. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2006; 103:9136-9141.
27. Chen D and Yang H. Integrated analysis of differentially 
expressed genes in breast cancer pathogenesis. Oncology 
letters. 2015; 9:2560-2566.
28. Liang Z, Ahn J, Guo D, Votaw JR and Shim H. 
MicroRNA-302 replacement therapy sensitizes breast 
cancer cells to ionizing radiation. Pharmaceutical research. 
2013; 30:1008-1016.
29. De Cecco L, Berardi M, Sommariva M, Cataldo A, Canevari 
S, Mezzanzanica D, Iorio MV, Tagliabue E and Balsari A. 
Increased sensitivity to chemotherapy induced by CpG-
ODN treatment is mediated by microRNA modulation. PloS 
one. 2013; 8:e58849.
30. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young 
RA and Dynlacht BD. E2F integrates cell cycle progression 
with DNA repair, replication, and G(2)/M checkpoints. 
Genes & development. 2002; 16:245-256.
31. Blattner C, Sparks A and Lane D. Transcription factor E2F-
1 is upregulated in response to DNA damage in a manner 
analogous to that of p53. Molecular and cellular biology. 
1999; 19:3704-3713.
32. O’Connor DJ and Lu X. Stress signals induce 
transcriptionally inactive E2F-1 independently of p53 and 
Rb. Oncogene. 2000; 19:2369-2376.
33. Lin WC, Lin FT and Nevins JR. Selective induction of 
E2F1 in response to DNA damage, mediated by ATM-
dependent phosphorylation. Genes & development. 2001; 
15:1833-1844.
34. Shiloh Y and Ziv Y. The ATM protein kinase: regulating 
the cellular response to genotoxic stress, and more. Nat Rev 
Mol Cell Biol. 2013; 14:197-210.
35. McKinnon PJ. ATM and the molecular pathogenesis of 
ataxia telangiectasia. Annual review of pathology. 2012; 
7:303-321.
36. Berkovich E and Ginsberg D. ATM is a target for positive 
regulation by E2F-1. Oncogene. 2003; 22:161-167.
37. Lavin MF. Ataxia-telangiectasia: from a rare disorder to 
a paradigm for cell signalling and cancer. Nature reviews 
Molecular cell biology. 2008; 9:759-769.
38. O’Driscoll M and Jeggo PA. The role of double-strand 
break repair - insights from human genetics. Nature reviews 
Genetics. 2006; 7:45-54.
39. Ransburgh DJ, Chiba N, Ishioka C, Toland AE and Parvin 
JD. Identification of breast tumor mutations in BRCA1 that 
abolish its function in homologous DNA recombination. 
Cancer research. 2010; 70:988-995.
40. Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue 
A, Daou S, Barbour H, Corbeil L, Hebert J, Drobetsky E, 
Masson JY, Di Noia JM and Affar el B. Tumor suppressor 
and deubiquitinase BAP1 promotes DNA double-strand 
break repair. Proceedings of the National Academy of 
Sciences of the United States of America. 2014; 111:285-
290.
Oncotarget797www.impactjournals.com/oncotarget
41. Hummel R, Hussey DJ and Haier J. MicroRNAs: predictors 
and modifiers of chemo- and radiotherapy in different 
tumour types. European journal of cancer. 2010; 46:298-
311.
42. Ma J, Dong C and Ji C. MicroRNA and drug resistance. 
Cancer gene therapy. 2010; 17:523-531.
43. Shiloh Y. ATM: expanding roles as a chief guardian 
of genome stability. Experimental cell research. 2014; 
329:154-161.
44. Kothandapani A, Dangeti VS, Brown AR, Banze LA, Wang 
XH, Sobol RW and Patrick SM. Novel role of base excision 
repair in mediating cisplatin cytotoxicity. The Journal of 
biological chemistry. 2011; 286:14564-14574.
45. Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini 
P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi 
T, Taccioli C, Tagliabue E, Iorio MV and Croce CM. 
Oncosuppressive role of p53-induced miR-205 in triple 
negative breast cancer. Molecular oncology. 2012; 6:458-
472.
46. Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin WG, Jr. 
and Livingston DM. Negative regulation of the growth-
promoting transcription factor E2F-1 by a stably bound 
cyclin A-dependent protein kinase. Cell. 1994; 78:161-172.
47. Palmieri D, D’Angelo D, Valentino T, De Martino I, 
Ferraro A, Wierinckx A, Fedele M, Trouillas J and Fusco 
A. Downregulation of HMGA-targeting microRNAs has a 
critical role in human pituitary tumorigenesis. Oncogene. 
2012; 31:3857-3865.
